On Thursday, Tryton announced that it has “received conditional approval for a clinical trial to test its stent system for the treatment of coronary artery disease.” Tryton’s stent system has already been approved in Europe.
Greg Davis, Tryton’s CEO, joined the organization in 2008 and prompted Tryton’s move to North Carolina. He is an internationally experienced medical device executive, including time in Asia as president of Guidant Japan. Greg is a familiar face at CED’s Biotech Forums and Venture Conference. He was also chairman of CED’s Medtech Conference committee in 2009. Greg also serves as chairman for ibiliti and helped mold the medtech10 conference hosted by ibiliti last week.
For more information, read TBJ’s full article: http://www.bizjournals.com/triangle/news/2010/12/02/durhams-tryton-gets-fda-go-ahead.html?surround=etf&ana=e_article
Monday, December 6, 2010
Tryton Medical Receives Approval for Clinical Trials
Tryton Medical was founded in 2003 in Massachusetts and joined CED in 2008 after they relocated to the Triangle. They now have 25 employees and $37M in funding, including a $20M series D round in September.